Is Corcept Therapeutics Stock Built to Withstand More Downside?
Corcept Therapeutics (CORT) stock is down 12.1% in a day. The recent slide reflects concerns over relacorilant’s FDA outcome, lower analyst sales forecasts, and a prolonged legal battle, but sharp drops like this often raise a tougher question: is the weakness temporary, or a sign of deeper cracks in the story?
Before judging its downturn reslience, let’s look at where Corcept Therapeutics stands today.
- Size: Corcept Therapeutics is a $7.3 Bil company with $741 Mil in revenue currently trading at $70.19.
- Fundamentals: Last 12 month revenue growth of 17.9% and operating margin of 8.8%.
- Liquidity: Has Debt to Equity ratio of 0.0 and Cash to Assets ratio of 0.51
- Valuation: Corcept Therapeutics stock is currently trading at P/E multiple of 68.5 and P/EBIT multiple of 110.8
- Has returned (median) -19.1% within a year following sharp dips since 2010. See CORT Dip Buy Analysis.
These metrics point to a Strong operational performance, alongside Very High valuation – making the stock Relatively Expensive. For details, see Buy or Sell CORT Stock
That brings us to the key consideration for investors worried about this fall: how resilient is CORT stock if markets turn south? This is where our downturn resilience framework comes in. Suppose CORT stock falls another 20-30% to $49 – can investors comfortably hold on? Turns out, the stock has fared worse than the S&P 500 index during various economic downturns, based on (a) how much the stock fell and, (b) how quickly it recovered. Below, we dive deeper into each such downturn.
2022 Inflation Shock
- CORT stock fell 45.9% from a high of $30.56 on 8 February 2021 to $16.53 on 27 January 2022 vs. a peak-to-trough decline of 25.4% for the S&P 500.
- However, the stock fully recovered to its pre-Crisis peak by 3 August 2023
- Since then, the stock increased to a high of $114.22 on 31 March 2025 , and currently trades at $70.19
| CORT | S&P 500 | |
|---|---|---|
| % Change from Pre-Recession Peak | -45.9% | -25.4% |
| Time to Full Recovery | 553 days | 464 days |
2020 Covid Pandemic
- CORT stock fell 31.8% from a high of $18.26 on 22 June 2020 to $12.46 on 27 August 2020 vs. a peak-to-trough decline of 33.9% for the S&P 500.
- However, the stock fully recovered to its pre-Crisis peak by 2 September 2020
| CORT | S&P 500 | |
|---|---|---|
| % Change from Pre-Recession Peak | -31.8% | -33.9% |
| Time to Full Recovery | 6 days | 148 days |
2018 Correction
- CORT stock fell 61.6% from a high of $25.50 on 29 January 2018 to $9.78 on 31 May 2019 vs. a peak-to-trough decline of 19.8% for the S&P 500.
- However, the stock fully recovered to its pre-Crisis peak by 14 December 2020
| CORT | S&P 500 | |
|---|---|---|
| % Change from Pre-Recession Peak | -61.6% | -19.8% |
| Time to Full Recovery | 563 days | 120 days |
2008 Global Financial Crisis
- CORT stock fell 85.3% from a high of $5.10 on 1 October 2007 to $0.75 on 2 February 2009 vs. a peak-to-trough decline of 56.8% for the S&P 500.
- However, the stock fully recovered to its pre-Crisis peak by 18 March 2015
| CORT | S&P 500 | |
|---|---|---|
| % Change from Pre-Recession Peak | -85.3% | -56.8% |
| Time to Full Recovery | 2,235 days | 1,480 days |
Feeling jittery about CORT stock? Consider portfolio approach.
Stock Picking Falls Short Against Multi Asset Portfolios
Individual picks are volatile but diversified assets offset each other. A multi asset portfolio helps you stay the course capture upside and reduce downside.
The asset allocation framework of Trefis’ Boston-based, wealth management partner yielded positive returns during the 2008-09 period when the S&P lost more than 40%. Our partner’ strategy now includes Trefis High Quality Portfolio, which has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices